Compound Detail
CHEMBL953
ENTACAPONE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL953 |
| Name | ENTACAPONE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | JRURYQJSLYLRLN-BJMVGYQFSA-N |
| Therapeutic | ✓ Yes |
8
Targets
19
Activities
2
Assay Types
30
PK Parameters
20
Publications
10
Known Names
7
Indications
1
Mechanisms
Molecular Properties
305.3
MW (Da)
1.78
ALogP
6
HBA
2
HBD
127.7
PSA (Ų)
0.28
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1998 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Catechol O-methyltransferase inhibitor | INHIBITOR | Catechol O-methyltransferase | ✓ | ✓ |
Indications
Parkinson Disease Cocaine-Related Disorders Cocaine-Related Disorders Epilepsy Obesity Amphetamine-Related Disorders Gastrointestinal Stromal Tumors
ATC Classification
N04BX02
entacapone
Level 1: NERVOUS SYSTEM
Level 2: ANTI-PARKINSON DRUGS
Activity Summary
IC50 17 meas. best 8.52
EC50 2 meas. best 5.25
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Catechol O-methyltransferase CHEMBL2372 | IC50 | 8.52 | 7.07 | 3.0 | 7 |
| Catechol O-methyltransferase CHEMBL2023 | IC50 | 7.22 | 6.815 | 60.0 | 2 |
| Unchecked CHEMBL612545 | IC50 | 5.72 | 5.72 | 1900.0 | 1 |
| Alpha-ketoglutarate-dependent dioxygenase FTO CHEMBL2331065 | IC50 | 5.52 | 5.48 | 3000.0 | 3 |
| G-protein coupled receptor 35 CHEMBL1293267 | EC50 | 5.25 | 4.715 | 5660.0 | 2 |
| ATP-binding cassette sub-family C member 4 CHEMBL1743128 | IC50 | 5.17 | 5.17 | 6800.0 | 1 |
| ATP-binding cassette sub-family C member 3 CHEMBL5918 | IC50 | 4.46 | 4.46 | 35100.0 | 1 |
| Bile salt export pump CHEMBL6020 | IC50 | 4.25 | 4.25 | 55600.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 1615.9 | ng.hr.mL-1 | Homo sapiens |
| CL | 11.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 5.3 | mL.min-1.kg-1 | Homo sapiens |
| CL | 11.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 12.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | - | mL.min-1.kg-1 | Homo sapiens |
| CL | 12.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 27.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 27.0 | mL.min-1.g-1 | Homo sapiens |
| CL | - | - | Homo sapiens |
| CL | 850.0 | mL/min | Homo sapiens |
| Cmax | 3930.69 | nM | Homo sapiens |
| Excretion | 10.0 | % | Homo sapiens |
| Excretion | 90.0 | % | Homo sapiens |
| F | 35.0 | % | Homo sapiens |
| Fu | 0.02 | - | Homo sapiens |
| Fu | 0.02 | - | Homo sapiens |
| Fu | 0.025 | - | Homo sapiens |
| Fu | 0.031 | - | Macaca fascicularis |
| Fu | 0.02 | - | Canis lupus familiaris |
| Fu | 0.019 | - | Cavia porcellus |
| Fu | 0.026 | - | Mus musculus |
| Fu | 0.017 | - | Rattus norvegicus |
| Fu | 1.0 | - | Homo sapiens |
| Fu | - | - | Homo sapiens |
| Fu | 0.021 | - | Rattus norvegicus |
| Inhibition | 65.0 | % | Homo sapiens |
| Inhibition | 82.0 | % | Homo sapiens |
| MRT | 0.38 | hr | Homo sapiens |
| T1/2 | 0.9667 | hr | Oryctolagus cuniculus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine